Screener
Corcept Therapeutics CORT Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Corcept Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:14 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028902
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash paid to satisfy statutory withholding requirement for net settlement of cashless option exercises and vesting of restricted stock grants | (5,761) | (15,825) |
| Net cash provided by (used in) financing activities | 760 | (39,803) |
| Net effect of exchange rate changes on cash, cash equivalents and restricted cash | (287) | 358 |
| Net decrease in cash, cash equivalents and restricted cash | (11,757) | (37,846) |
| Cash, cash equivalents and restricted cash, at beginning of period | 121,745 | 128,665 |
| Cash, cash equivalents and restricted cash, at end of period | $109,988 | $90,819 |
| Supplemental disclosure: | ||
| Exercise cost of shares repurchased for net settlement of cashless option exercises | $4,341 | $5,261 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Corcept Therapeutics's net change in cash?
- Corcept Therapeutics (CORT) reported net change in cash of -$11.76M in Q1 2026.
- How has Corcept Therapeutics's net change in cash changed year-over-year?
- Corcept Therapeutics's net change in cash increased by 68.9% year-over-year, from -$37.85M to -$11.76M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Corcept Therapeutics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude